No Data
No Data
Norstar (301333.SZ): Cumulative repurchased 1.49% of shares.
Grain Exchange reported on December 2nd that Norsge (301333.SZ) announced that as of November 30, 2024, the company has repurchased a total of 1,442,000 shares through a repurchase dedicated securities account through centralized auction trading, accounting for approximately 1.49% of the company's current total share capital of 96,581,256 shares. The highest fill price was 43.15 yuan/share, the lowest fill price was 35.06 yuan/share, and the total transaction amount was 56,062,734.00 yuan (excluding transaction costs).
Norse (301333): A leading clinical CRO steadily improving operation efficiency.
Clinical CSRO leading enterprise, with a fully integrated layout, the company has a complete service capability throughout the clinical trial chain, with main businesses including clinical trial operation services, clinical trial on-site management services, biological sample testing services, data management and statistics.
Express News | Summary of shareholding reductions by listed companies on November 14.
The shareholders of Norsg (301333.SZ), Harmony Growth Phase II and Harmony Health, intend to reduce their shareholding by no more than 2.56 million shares.
Nossige (301333.SZ) announced that the company's shareholders, Harmony Growth Phase II and Harmony Health, intend to reduce their shareholding in the company, ...
Express News | Novatec: Shareholder with a shareholding of over 5% plans to reduce no more than 2.7%.
Norsen (301333) 2024 Q3 financial report review: Profit is under pressure, taking multiple measures with a focus on the long term.
Describing the event, the company released the third quarter report for 2024, achieving revenue of 0.562 billion yuan in the first three quarters of 2024, an increase of 7.10% year-on-year; achieving a net income attributable to the parent company of 0.084 billion yuan, a decrease of 32.93% year-on-year;
No Data